+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Inhalable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2019

  • ID: 4772322
  • Report
  • 214 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Canigma A.L LTD
  • iDTx Systems, Inc.
  • Kanabo Research Ltd
  • Medspray BV
  • Next Safety, Inc.
  • MORE
Inhalable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2019

Summary

The Medical Devices sector report, “Inhalable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2019" provides an overview of Inhalable Drug Delivery Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inhalable Drug Delivery Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Inhalable Drug Delivery Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inhalable Drug Delivery Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inhalable Drug Delivery Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Canigma A.L LTD
  • iDTx Systems, Inc.
  • Kanabo Research Ltd
  • Medspray BV
  • Next Safety, Inc.
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Inhalable Drug Delivery Devices Overview

3 Products under Development
3.1 Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development
3.2 Inhalable Drug Delivery Devices - Pipeline Products by Segment
3.3 Inhalable Drug Delivery Devices - Pipeline Products by Territory
3.4 Inhalable Drug Delivery Devices - Pipeline Products by Regulatory Path
3.5 Inhalable Drug Delivery Devices - Pipeline Products by Estimated Approval Date
3.6 Inhalable Drug Delivery Devices - Ongoing Clinical Trials

4 Inhalable Drug Delivery Devices - Pipeline Products under Development by Companies
4.1 Inhalable Drug Delivery Devices Companies - Pipeline Products by Stage of Development
4.2 Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development

5 Inhalable Drug Delivery Companies and Product Overview
5.1 Acorda Therapeutics Inc Company Overview
5.2 Baxter International Inc Company Overview
5.3 Bellerophon Therapeutics Inc Company Overview
5.4 Breath Therapeutics Holding BV Company Overview
5.5 Canigma A.L LTD Company Overview
5.6 Edixomed Ltd Company Overview
5.7 iDTx Systems, Inc. Company Overview
5.8 Impel NeuroPharma Inc Company Overview
5.9 Kanabo Research Ltd Company Overview
5.10 Mallinckrodt Plc Company Overview
5.11 Medical Developments International Ltd Company Overview
5.12 Medspray BV Company Overview
5.13 NeuroproteXeon Inc Company Overview
5.14 Next Safety, Inc. Company Overview
5.15 Nobilis Therapeutics Inc Company Overview
5.16 Sandoz International GmbH Company Overview
5.17 Texas Tech University Health Sciences Center Company Overview
5.18 University of Texas Health Science Center at Houston Company Overview
5.19 Vectura Group Plc Company Overview
5.20 Vero Biotech LLC Company Overview
5.21 VitalMIST Company Overview
5.22 Windtree Therapeutics Inc Company Overview

6 Inhalable Drug Delivery Devices - Recent Developments
6.1 Apr 30, 2019: Windtree Therapeutics appoints Daniel Geffken to Board of Directors
6.2 Apr 26, 2019: AstraZeneca: Q1 2019 results
6.3 Apr 25, 2019: Baxter reports first-quarter 2019 results
6.4 Apr 23, 2019: Catalent invests $14 million at Its Eberbach, Germany Softgel facility
6.5 Apr 12, 2019: Inhalation Sciences wins place on prestigious EU-funded Life Science Investment Hotlist
6.6 Apr 11, 2019: Catalent Celebrates opening of second Shanghai facility to optimize global and local clinical supply solutions for China
6.7 Apr 05, 2019: JC Pharma plans stock exchange listing to develop CannatolRx
6.8 Apr 02, 2019: 3M Drug Delivery Systems relocates UK R&D to new, state-of-the-art facility
6.9 Apr 01, 2019: Inhalation Sciences receives new Contract Research order for DissolvIt
6.10 Apr 01, 2019: Vectura Group names Kevin Matthews to its board of directors

7 Appendix
7.1 Methodology
7.2 About the Author
7.3 Contact Us
7.4 Disclaimer

List of Tables
  • Table 1: Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development
  • Table 2: Inhalable Drug Delivery Devices - Pipeline Products by Segment
  • Table 3: Inhalable Drug Delivery Devices - Pipeline Products by Territory
  • Table 4: Inhalable Drug Delivery Devices - Pipeline Products by Regulatory Path
  • Table 5: Inhalable Drug Delivery Devices - Pipeline Products by Estimated Approval Date
  • Table 6: Inhalable Drug Delivery Devices - Ongoing Clinical Trials
  • Table 7: Inhalable Drug Delivery Companies - Pipeline Products by Stage of Development
  • Table 8: Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development
  • Table 9: Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: Drug Delivery Device - Neonatal Respiratory Distress Syndrome (RDS) - Product Status
  • Table 11: Drug Delivery Device - Neonatal Respiratory Distress Syndrome (RDS) - Product Description
  • Table 12: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 13: ProMaxx Microsphere - Product Status
  • Table 14: ProMaxx Microsphere - Product Description
  • Table 15: Bellerophon Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 16: INOpulse - Product Status
  • Table 17: INOpulse - Product Description
  • Table 18: Bellerophon Therapeutics Inc - Ongoing Clinical Trials Overview
  • Table 19: INOpulse - A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects with Pulmonary Hypertension Associated with Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-label Long Term Extension Safety Study
  • Table 20: INOpulse - A Phase 3, Placebo Controlled, Double-blind, Randomized, Clinical Study to Determine Efficacy, Safety, and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Symptomatic Subjects with PAH (Part 1 and Part 2)
  • Table 21: INOpulse - A Randomized, Double-blind, Placebo-controlled Dose Escalation Study to Assess the Safety and Efficacy of Pulsed iNO in Subjects with Pulmonary Hypertension Associated with Pulmonary Fibrosis on Long Term Oxygen Therapy
  • Table 22: INOpulse - An Open-label Long-term Safety Study of Inhaled Nitric Oxide (iNO) for PAH
  • Table 23: INOpulse - INOvation-2 Clinical Study of INOpulse Device
  • Table 24: INOpulse - Phase IIb Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects in Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD)
  • Table 25: Breath Therapeutics Holding BV Pipeline Products & Ongoing Clinical Trials Overview
  • Table 26: Lung-Targeted BOS Device - Product Status
  • Table 27: Lung-Targeted BOS Device - Product Description
  • Table 28: Breath Therapeutics Holding BV - Ongoing Clinical Trials Overview
  • Table 29: Lung-Targeted BOS Device - A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine a (L-CsA) Inhalation Solution Delivered via the Pari Investigational eFlow Device plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Double Lung Transplantation
  • Table 30: Lung-Targeted BOS Device - A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow Device Plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single Lung Transplantation
  • Table 31: Canigma A.L LTD Pipeline Products & Ongoing Clinical Trials Overview
  • Table 32: Vaporiser Device - Product Status
  • Table 33: Vaporiser Device - Product Description
  • Table 34: Edixomed Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 35: NOx System - Cystic Fibrosis - Product Status
  • Table 36: NOx System - Cystic Fibrosis - Product Description
  • Table 37: NOx System - VAP - Product Status
  • Table 38: NOx System - VAP - Product Description
  • Table 39: iDTx Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 40: GoPilot - Product Status
  • Table 41: GoPilot - Product Description
  • Table 42: Impel NeuroPharma Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 43: POD Device - Product Status
  • Table 44: POD Device - Product Description
  • Table 45: Impel NeuroPharma Inc - Ongoing Clinical Trials Overview
  • Table 46: POD Device - A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Benserazide to L-dopa Responsive Parkinson's Disease Patients
  • Table 47: POD Device - Comparison of Devices for Intranasal Delivery of Insulin
  • Table 48: POD Device - Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal Dihydroergotamine Mesylate (DHE) Administered Using the I123 Precision Olfactory Delivery (POD) Device [INP104, POD-DHE] in Patients with Migraine Headache: Stop 301 Trial (Safety and Tolerability of POD-DHE)
  • Table 49: Kanabo Research Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 50: Next Generation Smart VapePod MD Vaporizer - Product Status
  • Table 51: Next Generation Smart VapePod MD Vaporizer - Product Description
  • Table 52: VapePod - Product Status
  • Table 53: VapePod - Product Description
  • Table 54: Mallinckrodt Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 55: Next Generation Inomax Evolve - Product Status
  • Table 56: Next Generation Inomax Evolve - Product Description
  • Table 57: Medical Developments International Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 58: Penthrox Inhaler - Product Status
  • Table 59: Penthrox Inhaler - Product Description
  • Table 60: Penthrox Inhaler - Paediatric - Product Status
  • Table 61: Penthrox Inhaler - Paediatric - Product Description
List of Figures
  • Figure 1: Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development
  • Figure 2: Inhalable Drug Delivery Devices - Pipeline Products by Segment
  • Figure 3: Inhalable Drug Delivery Devices - Pipeline Products by Territory
  • Figure 4: Inhalable Drug Delivery Devices - Pipeline Products by Regulatory Path
  • Figure 5: Inhalable Drug Delivery Devices - Pipeline Products by Estimated Approval Date
  • Figure 6: Inhalable Drug Delivery Devices - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Acorda Therapeutics Inc
  • Baxter International Inc
  • Bellerophon Therapeutics Inc
  • Breath Therapeutics Holding BV
  • Canigma A.L LTD
  • Edixomed Ltd
  • iDTx Systems, Inc.
  • Impel NeuroPharma Inc
  • Kanabo Research Ltd
  • Mallinckrodt Plc
  • Medical Developments International Ltd
  • Medspray BV
  • NeuroproteXeon Inc
  • Next Safety, Inc.
  • Nobilis Therapeutics Inc
  • Sandoz International GmbH
  • Texas Tech University Health Sciences Center
  • University of Texas Health Science Center at Houston
  • Vectura Group Plc
  • Vero Biotech LLC
  • VitalMIST
  • Windtree Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll